Aeterna begins third pivotal trial of Neovastat

Aeterna (AELA; TSE:AEL) began a pivotal Phase II trial of its Neovastat (AE941) oral inhibitor of angiogenesis as monotherapy in 120 patients with progressive multiple myeloma in North America and Eur...